The proposed studies are designed to determine the clinical significance of MARCO expression by inflammatory monocytes and macrophages in lesional skin biopsies of scleroderma patients, as well as evaluating the effects and determining the mechanisms of carboxylated poly(lactic-co-glycolic acid) (PLGA) nanoparticle therapy that targets MARCO+ inflammatory monocytes and macrophages on the solution of skin fibrosis using mouse models of scleroderma. This work should provide critical pre-clinical information relevant to the translation and clinical testing of the PLGA nanoparticle platform for the treatment of scleroderma.
|Effective start/end date||9/1/18 → 8/31/21|
- Scleroderma Foundation (AGMT 1/29/18)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.